China-based AIM Vaccine Co., Ltd plans to make an initial public offering (IPO) of 9.71 million shares to the Hong Kong Stock Exchange at HKD 16.16 ($2.06) per share on October 6, 2022. The proceeds from the HKD 181 million ($23 million) IPO will be used to fund vaccine research and development, expand the vaccine pipeline, construct new facilities, and support marketing activities.
Company Overview and Vaccine Platforms
Founded in 2011, AIM Vaccine has established itself as a leading vaccine developer with eight commercialized vaccines. The company’s portfolio covers a range of diseases, including rabies, hepatitis B virus, hepatitis A virus, mumps, hemorrhagic fever with renal syndrome, and meningococcal disease. AIM Vaccine also operates five advanced vaccine platforms: bacterial vaccine, virus vaccine, genetic engineering vaccine, combined vaccine, and mRNA vaccine. It is the only Chinese vaccine company with all five proven human vaccine platform technologies worldwide.
Financial Performance
During the first four months of 2022, AIM Vaccine generated RMB 275 million ($38.7 million) in revenues and reported RMB 93.83 million ($13.2 million) in net losses. The IPO is expected to provide the company with additional capital to accelerate its growth and innovation in the vaccine sector.
Future Outlook
The IPO marks a significant milestone for AIM Vaccine as it seeks to enhance its position in the global vaccine market. With the funds raised, the company aims to advance its vaccine development efforts, expand its pipeline, and build new facilities to meet growing demand. This strategic move underscores AIM Vaccine’s commitment to innovation and improving public health through advanced vaccine technologies.-Fineline Info & Tech
